AbbVie Inc. $ABBV Shares Purchased by Schroder Investment Management Group

Schroder Investment Management Group grew its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 9.5% in the third quarter, according to its most recent filing with the SEC. The firm owned 2,808,337 shares of the company’s stock after acquiring an additional 243,666 shares during the quarter. Schroder Investment Management Group’s holdings in AbbVie were worth $650,242,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of ABBV. Gerber Kawasaki Wealth & Investment Management boosted its holdings in shares of AbbVie by 4.2% in the third quarter. Gerber Kawasaki Wealth & Investment Management now owns 4,542 shares of the company’s stock valued at $1,052,000 after acquiring an additional 183 shares in the last quarter. PFG Advisors raised its holdings in AbbVie by 8.8% during the third quarter. PFG Advisors now owns 31,980 shares of the company’s stock worth $7,405,000 after purchasing an additional 2,577 shares in the last quarter. ProVise Management Group LLC raised its holdings in AbbVie by 0.5% during the third quarter. ProVise Management Group LLC now owns 10,386 shares of the company’s stock worth $2,405,000 after purchasing an additional 50 shares in the last quarter. Altman Advisors Inc. lifted its position in AbbVie by 0.5% in the third quarter. Altman Advisors Inc. now owns 15,874 shares of the company’s stock worth $3,675,000 after purchasing an additional 84 shares during the period. Finally, Pinnacle Associates Ltd. boosted its stake in AbbVie by 1.7% during the 3rd quarter. Pinnacle Associates Ltd. now owns 171,419 shares of the company’s stock valued at $39,690,000 after purchasing an additional 2,859 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Citigroup lowered their price target on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 27th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, January 21st. Royal Bank Of Canada began coverage on shares of AbbVie in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price target on the stock. The Goldman Sachs Group reissued a “neutral” rating and issued a $223.00 price target on shares of AbbVie in a report on Wednesday, January 28th. Finally, Wall Street Zen upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 28th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $253.15.

AbbVie Stock Down 0.8%

Shares of AbbVie stock opened at $230.41 on Monday. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81. The firm has a market capitalization of $407.40 billion, a PE ratio of 97.63, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34. The stock’s fifty day moving average is $224.72 and its 200-day moving average is $224.21.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.AbbVie’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter last year, the company posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. AbbVie’s payout ratio is currently 293.22%.

Insider Activity at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. The trade was a 66.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. The trade was a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.08% of the stock is currently owned by corporate insiders.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.